175 related articles for article (PubMed ID: 32222038)
1. Burden of asthma exacerbations and health care utilization in pediatric patients with asthma in the US and England.
Gokhale M; Hattori T; Evitt L; Lenney W; Nordstrom B; Collins J; Schultze A; Van Dyke MK
Immun Inflamm Dis; 2020 Jun; 8(2):236-245. PubMed ID: 32222038
[TBL] [Abstract][Full Text] [Related]
2. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA.
Suruki RY; Daugherty JB; Boudiaf N; Albers FC
BMC Pulm Med; 2017 Apr; 17(1):74. PubMed ID: 28449686
[TBL] [Abstract][Full Text] [Related]
3. The prevalence and disease burden of severe eosinophilic asthma in Japan.
Nagasaki T; Sato K; Kume N; Oguma T; Sunadome H; Ito I; Izuhara Y; Okamoto K; Kobayashi S; Ohno T; Mizukami A; Kobayashi A; Kaise T; Kuroda T; Mishima M; Matsumoto H
J Asthma; 2019 Nov; 56(11):1147-1158. PubMed ID: 30822174
[No Abstract] [Full Text] [Related]
4. The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization.
Viinanen A; Lassenius MI; Toppila I; Karlsson A; Veijalainen L; Idänpään-Heikkilä JJ; Laitinen T
J Asthma; 2020 Oct; 57(10):1092-1102. PubMed ID: 31267775
[No Abstract] [Full Text] [Related]
5. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP
Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888
[No Abstract] [Full Text] [Related]
6. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
Trevor J; Lugogo N; Carr W; Moore WC; Soong W; Panettieri RA; Desai P; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):579-587.e1. PubMed ID: 34273485
[TBL] [Abstract][Full Text] [Related]
7. Real-world patterns and implications of short-acting β
Lugogo N; Gilbert I; Tkacz J; Gandhi H; Goshi N; Lanz MJ
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):681-689.e1. PubMed ID: 33515710
[TBL] [Abstract][Full Text] [Related]
8. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
Sicras-Mainar A; Capel M; Navarro-Artieda R; Nuevo J; Orellana M; Resler G
J Med Econ; 2020 May; 23(5):492-500. PubMed ID: 31958257
[No Abstract] [Full Text] [Related]
9. Uncontrolled asthma across GINA treatment steps 2 - 5 in a large US patient cohort.
Busse WW; Fang J; Marvel J; Tian H; Altman P; Cao H
J Asthma; 2022 May; 59(5):1051-1062. PubMed ID: 33709871
[TBL] [Abstract][Full Text] [Related]
10. Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy.
Schatz M; Meckley LM; Kim M; Stockwell BT; Castro M
J Allergy Clin Immunol Pract; 2014; 2(5):570-4.e1. PubMed ID: 25213050
[TBL] [Abstract][Full Text] [Related]
11. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
12. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
Friedman HS; Yawn BP
Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
14. Real life data on incidence and risk factors of severe asthma exacerbations in children in primary care.
Engelkes M; Janssens HM; de Ridder MA; Sturkenboom MC; de Jongste JC; Verhamme KM
Respir Med; 2016 Oct; 119():48-54. PubMed ID: 27692147
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological, clinical and economic burden of severe eosinophilic asthma in Taiwan: Results from a large tertiary care hospital.
Shantakumar S; Ho YF; Tuan LW; Lin TM; Hershko AY; Chen YH
Asian Pac J Allergy Immunol; 2023 Dec; 41(4):325-335. PubMed ID: 33274956
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.
Chen HC; Huang CD; Chang E; Kuo HP
BMC Pulm Med; 2016 Jan; 16():3. PubMed ID: 26747278
[TBL] [Abstract][Full Text] [Related]
17. Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab.
Ke X; Kavati A; Wertz D; Huang Q; Wang L; Willey VJ; Stephenson JJ; Ortiz B; Panettieri RA; Corren J
Clin Ther; 2018 Jul; 40(7):1140-1158.e4. PubMed ID: 30049502
[TBL] [Abstract][Full Text] [Related]
18. Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study.
Ortega H; Hahn B; Tran JN; Bell C; Shams SA; Llanos JP
Allergy Asthma Proc; 2019 May; 40(3):146-153. PubMed ID: 30925945
[No Abstract] [Full Text] [Related]
19. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
20. Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts.
Müllerová H; Hahn B; Simard EP; Mu G; Hatipoğlu U
Int J Chron Obstruct Pulmon Dis; 2019; 14():683-692. PubMed ID: 30962682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
